Discouraging results from a phase II study evaluating AbbVie’s ABBV promising cancer candidate rovalpituzumab tesirine or Rova-T in third-line or later small cell lung cancer (“SCLC”) grabbed ...
Transaction Expanded To Include Contracts To Operate and Maintain ROVA and Four Other Power Plants Westmoreland Coal Company (AMEX:WLB) announced today that it has completed a transaction with ...
AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far. As it searched for new ...
AbbVie's Rova-T Falls Short in Key Lung Cancer Study: AbbVie's promising cancer candidate, rovalpituzumab tesirine or Rova-T fell short of expectations in a phase II TRINITY study evaluating it in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results